Patent application number | Description | Published |
20110007512 | Directional Light Source Using Refractive and Reflective Optics - A directional light source comprising refractive and reflective optics is disclosed. In one embodiment, the system comprises refracting apparatus which refracts light into a narrow cone, and reflecting apparatus which recycles light into a direction such that light will emanate from the refracting apparatus in the desired narrow cone. | 01-13-2011 |
20110013387 | Directional Linear Light Source - An apparatus and method for providing a linear light source emitting light in a narrow cone of directions is disclosed. In one embodiment, the apparatus comprises a linear light source and a sheet designed in such a way that light is emanated out in a narrow set of directions. Also disclosed is a directional surface light source using a directional linear light source. | 01-20-2011 |
20110013418 | Apparatus for Efficiently Coupling Light from a Light Source into a Thin Object - An apparatus for efficiently coupling light from a light source into a thin object such as a rod or a sheet is disclosed. In an embodiment, the apparatus comprises a sheet and a linear light source placed along the edge of the sheet. The light from linear light source is coupled into the sheet using one or more concentrator blocks. In another embodiment, the apparatus comprises a rod and a point light source placed near one end of the rod. The light from point light source is coupled into the rod using one or more concentrator blocks. | 01-20-2011 |
20110182050 | Polarized Linear Light Source - An energy efficient polarized linear light source system is disclosed. In one embodiment, the system comprises a reflector and a reflecting polarizer. A transparent linear light source and a quarter wave retarder are placed in between the reflector and reflecting polarizer. The polarized linear light source may be used as an illuminator for an efficient polarized surface light source. | 07-28-2011 |
20110182055 | Photoluminescent Light Source - A photo luminescent light source is disclosed. In one embodiment, the apparatus comprises a light conducting medium. This light conducting medium includes particles of photoluminescent material, and a light source placed along an edge of it. The photoluminescent material absorbs light generated by the light source, and emanates light of the wavelength characterized by the photoluminescence properties of particles. The distribution of light emitting photoluminescent particles is varied throughout the medium to emanate a predetermined light pattern. In another embodiment, the light source emits light of multiple colors. In yet another embodiment, the light source emits polarized light. | 07-28-2011 |
Patent application number | Description | Published |
20090306129 | SUBSTITUTED PYRAZOLO [3,4-B] PYRIDINES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV Formula (XIV). | 12-10-2009 |
20100022571 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV. | 01-28-2010 |
20100029728 | PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of CNS diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and their use as PDE type IV selective inhibitors, are provided. | 02-04-2010 |
20100292196 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein having the structure of Formula 1: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE type 4/PDE type 7 inhibitors are provided. | 11-18-2010 |
20110021473 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV - The present invention relates to catechol derivatives of formula (I), which can be used as inhibitors of phosphodiesterase (PDPI) type 4 or type 7, Compounds disclosed herein can be useful in the treatment of CNS disorders, inflammatory diseases such as, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type 4 or type 7 inhibitors. | 01-27-2011 |
Patent application number | Description | Published |
20090048247 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV - The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors. | 02-19-2009 |
20110130403 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed hereinf having the structure of Formula I: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukaemia; especially in humans. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type 4, PDE type 7 and dual PDE t e 4/PDE t e 7 inhibitors are rovided. | 06-02-2011 |